ER-Golgi Secretory Pathway Dysfunction in PD

📖 Wiki Page

experiment1208 wordssynced 2026-04-02

Experiment Design: ER-Golgi Secretory Pathway Dysfunction in [Parkinson's Disease](/diseases/parkinsons-disease)

Experiment Overview

flowchart TD experiments_er_golgi_secretory["ER-Golgi Secretory Pathway Dysfunction in PD - E"] experiments_er_golgi_secretory["Experiment"] experiments_er_golgi_secretory -->|"related to"| experiments_er_golgi_secretory style experiments_er_golgi_secretory fill:#81c784,stroke:#333,color:#000 experiments_er_golgi_secretory["Design"] experiments_er_golgi_secretory -->|"related to"| experiments_er_golgi_secretory style experiments_er_golgi_secretory fill:#81c784,stroke:#333,color:#000 experiments_er_golgi_secretory["ER-Golgi"] experiments_er_golgi_secretory -->|"related to"| experiments_er_golgi_secretory style experiments_er_golgi_secretory fill:#81c784,stroke:#333,color:#000 experiments_er_golgi_secretory["Dysfunction"] experiments_er_golgi_secretory -->|"related to"| experiments_er_golgi_secretory style experiments_er_golgi_secretory fill:#81c784,stroke:#333,color:#000 style experiments_er_golgi_secretory fill:#4fc3f7,stroke:#333,color:#000

Objective: Validate the ER-Golgi Secretory Pathway Dysfunction Hypothesis in [Parkinson's Disease](/diseases/parkinsons-disease) by testing whether:

...

Experiment Design: ER-Golgi Secretory Pathway Dysfunction in [Parkinson's Disease](/diseases/parkinsons-disease)

Experiment Overview

Mermaid diagram (expand to render)

Objective: Validate the ER-Golgi Secretory Pathway Dysfunction Hypothesis in [Parkinson's Disease](/diseases/parkinsons-disease) by testing whether:

ER-Golgi dysfunction precedes [alpha-synuclein](/proteins/alpha-synuclein) aggregation in [dopaminergic neurons](/cell-types/dopaminergic-neurons)

Genetic risk factors ([GBA](/genes/gba), [VPS35](/genes/vps35), ATP13A9) cause ER-Golgi impairment

ER-Golgi modulators can prevent or reverse dopaminergic neurodegeneration

Study Design: Multi-phase, multi-arm translational study

Duration: 36 months (12 months per phase)

Phase 1: In Vitro Validation (Months 1-12)

Study 1.1: iPSC-Derived Dopaminergic Neuron Characterization

Objective

Characterize ER-Golgi function in dopaminergic neurons derived from PD patients with various genetic backgrounds.

Methods

Patient Cohorts:

Group 1: [GBA](/genes/gba) mutation carriers (n=5)
Group 2: [LRRK2](/genes/lrrk2) G2019S carriers (n=5)
Group 3: [VPS35](/genes/vps35) D620N carriers (n=3)
Group 4: Sporadic [PD](/diseases/parkinsons-disease) (n=5)
Group 5: Healthy controls (n=5)

Primary Endpoints:
| Endpoint | Method | Timepoint |
|----------|--------|-----------|
| ER stress markers | Western blot: p-PERK, p-eIF2α, CHOP, BiP | Day 0, 30, 60 |
| Golgi integrity | GM130 immunostaining + confocal microscopy | Day 0, 30, 60 |
| XBP1 splicing | qRT-PCR | Day 0, 30, 60 |
| [Alpha-synuclein](/proteins/alpha-synuclein) aggregation | pSer129-αSyn IHC | Day 0, 30, 60 |
| Viability | ATP assay + caspase 3/7 | Day 0, 30, 60 |

Secondary Endpoints:

Mitochondrial function: Seahorse XF analysis
Autophagy flux: LC3 II turnover
Calcium homeostasis: Fluo-4 AM imaging
Synaptic function: Synaptophysin/VGLUT2 puncta analysis

Sample Size Justification

Using ANOVA with 5 groups, α=0.05, power=0.80, effect size=0.5, requires n=3 minimum per group. Using n=5 for robustness.

Study 1.2: Toxin Model Time Course

Objective

Determine temporal relationship between ER-Golgi dysfunction and alpha-synuclein aggregation following toxin exposure.

Methods

Treatment Groups:

Vehicle control
MPTP (1μM, 24h)
6-OHDA (100μM, 24h)
Rotenone (10nM, 72h)
Paraquat (10μM, 72h)

Cell Type: iPSC-derived dopaminergic neurons (n=3 lines per group)

Timepoints: 2h, 6h, 12h, 24h, 48h, 72h post-treatment

Readouts:

Early markers (<6h):

ER calcium depletion (Fluo-5F AM)
p-PERK activation (Western blot)
Golgi dispersion (GM130 staining)

Intermediate markers (6-24h):

XBP1 splicing
CHOP expression
p-eIF2α

Late markers (24-72h):

Alpha-synuclein pSer129
Mitochondrial complex I activity
Cell viability

Statistical Analysis

Mixed-effects model with treatment × time interaction. Post-hoc Bonferroni correction.

Study 1.3: Therapeutic Intervention In Vitro

Objective

Test whether ER-Golgi modulators protect dopaminergic neurons from toxin-induced degeneration.

Methods

Intervention Arms:
| Compound | Dose | Mechanism | Source |
|----------|------|-----------|--------|
| TUDCA | 200μM | Chemical chaperone | Sigma-Aldrich |
| Guanabenz | 10μM | eIF2α phosphatase inhibitor | MedChemExpress |
| Salubrinal | 10μM | eIF2α phosphatase inhibitor | Selleck Chemicals |
| ISRIB | 5μM | ATF4 pathway modulator | Tocris |
| Vehicle | — | — | — |

Toxicity Challenge: MPTP 1μM for 24h (pre-treatment with compounds 1h prior)

Readouts: Cell viability, ER stress markers, Golgi integrity, alpha-synuclein aggregation

Analysis: IC50 determination, synergy assessment (Comburent analysis)

Phase 2: In Vivo Validation (Months 12-24)

Study 2.1: Mouse Model Characterization

Objective

Validate ER-Golgi dysfunction in established mouse models of PD.

Models

MPTP mouse model (C57BL/6, 8 weeks, male)

α-Synuclein transgenic (SNCA A53T, Jackson Labs)

GBA knockout (conditional in neurons)

VPS35 D620N knock-in

Experimental Design

MPTP Model:

Acute: MPTP 30mg/kg × 5 days, sacrifice day 1, 3, 7, 14
Chronic: MPTP 20mg/kg × 4 weeks, sacrifice week 1, 4, 8, 12
Controls: Saline-treated age-matched

Readouts:

Behavioral: Rotarod, cylinder, gait analysis (pre and post)
Histological: TH+ neuron count, pSer129-αSyn, IBA1 (microglia), GFAP (astrocytes)
Molecular: ER stress PCR array, Golgi integrity, mitochondrial complex I
Biochemical: Striatal dopamine, CSF biomarkers

Sample Size: n=12 per group (power 0.80, effect size 0.8)

Study 2.2: Pharmacological Intervention In Vivo

Objective

Test whether ER-Golgi modulators rescue dopaminergic neurons in vivo.

Methods

Treatment Groups (n=12 per group):

Vehicle (saline, i.p.)

MPTP + TUDCA (250mg/kg, i.p., daily)

MPTP + Guanabenz (2mg/kg, i.p., daily)

MPTP + Salubrinal (1mg/kg, i.p., daily)

Positive control: MPTP + CoQ10 (100mg/kg, i.p., daily)

Treatment Protocol:

Pre-treatment: 7 days
Co-treatment with MPTP: 14 days
Post-treatment observation: 28 days

Endpoints:

Primary: TH+ neuron survival in substantia nigra pars compacta
Secondary: Rotarod performance, striatal dopamine levels
Exploratory: ER stress markers (qPCR), Golgi morphology (EM)

Phase 3: Clinical Translation (Months 24-36)

Study 3.1: Biomarker Validation

Objective

Identify and validate ER-Golgi pathway biomarkers in PD patients.

Study Design

Prospective cohort study

Cohorts:

Early PD (n=50, H&Y 1-2)
Advanced PD (n=50, H&Y 3-4)
Prodromal RBD (n=30)
Healthy controls (n=30)

Biomarker Candidates:
| Biomarker | Source | Method | Pathway |
|----------|--------|--------|---------|
| BiP/GRP78 | CSF | ELISA | ER chaperone |
| XBP1s mRNA | PBMCs | qRT-PCR | UPR activation |
| p-PERK | Blood cells | Western blot | UPR activation |
| GM130 | Exosomes | Western blot | Golgi integrity |
| TUDCA | Urine | LC-MS | ER stress (metabolite) |

Correlation Analysis:

UPDRS motor score
Dopamine transporter imaging (DAT-SPECT)
CSF alpha-synuclein
Disease duration

Study 3.2: Proof-of-Concept Clinical Trial

Objective

Assess safety and preliminary efficacy of TUDCA in early PD patients.

Design

Randomized, double-blind, placebo-controlled

Population: Early PD (H&Y 1-2, n=60)

Arms (n=20 each):

TUDCA 500mg BID oral

TUDCA 1000mg BID oral

Placebo

Duration: 52 weeks

Endpoints:

Primary: Safety (adverse events)
Secondary: Change in UPDRS Part III, MoCA, CSF biomarkers
Exploratory: ER stress markers in blood, DAT-SPECT change

Statistical Analysis Plan

Primary Analysis

Mixed-effects models for repeated measures, with treatment as fixed effect, subject as random effect, baseline as covariate.

Multiple Comparison Correction

Bonferroni for primary endpoints, FDR for exploratory endpoints.

Power Calculations

In vitro: n=5 per group, power >0.80 for effect size 1.0
In vivo: n=12 per group, power >0.80 for effect size 0.8
Clinical: n=20 per group, power >0.80 for effect size 0.6

Success Criteria

Phase 1 Success

≥70% of patient-derived neurons show elevated ER stress markers
Time-course demonstrates ER-Golgi dysfunction precedes α-syn aggregation
≥1 compound shows ≥50% neuroprotection in vitro

Phase 2 Success

Mouse models confirm ER-Golgi dysfunction in vivo
≥1 compound shows ≥30% neuron rescue vs. MPTP alone
Behavioral improvements correlate with molecular markers

Phase 3 Success

Biomarker panel shows significant difference between PD and controls
TUDCA shows acceptable safety profile
Trend toward clinical benefit (UPDRS improvement ≥3 points)

Data Management

Electronic data capture (REDCap)
Centralized biobank (CSF, blood, tissue)
Blind coding for all experimental groups
Independent statistical review

Ethical Considerations

IRB approval for all human studies
IACUC approval for animal studies
Informed consent for patient cohorts
Data safety monitoring board for clinical trial

References

Hetz C, et al., Targeting ER stress in neurodegeneration. Nat Rev Drug Discov. 2023 (2023)

Saxena S, et al., ER stress in Parkinson's disease. J Neurochem. 2018 (2018)

Zhao Y, et al., Golgi fragmentation in neurodegeneration. J Neurosci Res. 2018 (2018)

Matus S, et al., TUDCA in neurodegeneration. Pharmacol Res. 2016 (2016)

Lindholm D, et al., ER stress and apoptosis. Cell Mol Life Sci. 2006 (2006)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design

Experiment Design: ER-Golgi Secretory Pathway Dysfunction in [Parkinson's Disease](/diseases/parkinsons-disease)

Experiment Overview

Experiment Design: ER-Golgi Secretory Pathway Dysfunction in [Parkinson's Disease](/diseases/parkinsons-disease)

Experiment Overview

Phase 1: In Vitro Validation (Months 1-12)

Study 1.1: iPSC-Derived Dopaminergic Neuron Characterization

Objective

Methods

Sample Size Justification

Study 1.2: Toxin Model Time Course

Objective

Methods

Statistical Analysis

Study 1.3: Therapeutic Intervention In Vitro

Objective

Methods

Phase 2: In Vivo Validation (Months 12-24)

Study 2.1: Mouse Model Characterization

Objective

Models

Experimental Design

Study 2.2: Pharmacological Intervention In Vivo

Objective

Methods

Phase 3: Clinical Translation (Months 24-36)

Study 3.1: Biomarker Validation

Objective

Study Design

Study 3.2: Proof-of-Concept Clinical Trial

Objective

Design

Statistical Analysis Plan

Primary Analysis

Multiple Comparison Correction

Power Calculations

Success Criteria

Phase 1 Success

Phase 2 Success

Phase 3 Success

Data Management

Ethical Considerations

References

See Also